Skip to main content

and
  1. Article

    Open Access

    Involvement of circulating CEA in liver metastases from colorectal cancers re-examined in a new experimental model

    Both experimental and clinical data show evidence of a correlation between elevated blood levels of carcinoembryonic antigen (CEA) and the development of liver metastases from colorectal carcinomas. However, a...

    A Leconte, V Garambois, M Ychou, B Robert, D Pourquier in British Journal of Cancer (1999)

  2. Article

    Open Access

    Potentiation of ionising radiation by targeting tumour necrosis factor alpha using a bispecific antibody in human pancreatic cancer

    The aim of this study was to treat carcinoembryonic antigen (CEA)-expressing pancreatic carcinoma cells with tumour necrosis factor alpha (TNFα) and simultaneous radiation therapy (RT), using a bispecific antibod...

    D Azria, C Larbouret, V Garambois, A Kramar, P Martineau in British Journal of Cancer (2003)

  3. Article

    Open Access

    p53 status and response to radiotherapy in rectal cancer: a prospective multilevel analysis

    The aim of this study was to evaluate, in a prospective study, the predictive role of p53 status analysed at four different levels in identifying the response to preoperative radiotherapy in rectal adenocarcin...

    E Lopez-Crapez, F Bibeau, S Thézenas, M Ychou in British Journal of Cancer (2005)

  4. Article

    Open Access

    Phase I trial of oxaliplatin with fluorouracil, folinic acid and concurrent radiotherapy for oesophageal cancer

    This dose escalation study was designed to determine the maximum tolerated dose (MTD) and recommended doses (RDs) of 5-fluorouracil (5FU), folinic acid and oxaliplatin (FOLFOX) with concomitant radiotherapy in...

    T Conroy, F Viret, E François, J F Seitz, V Boige, M Ducreux in British Journal of Cancer (2008)

  5. Article

    Open Access

    TP53 mutations predict disease control in metastatic colorectal cancer treated with cetuximab-based chemotherapy

    Recent studies have suggested that activation of the EGFR pathway leads to malignant transformation only if the p53 protein is inactivated. Therefore, we evaluated the impact of TP53 mutations on cetuximab-based ...

    A Oden-Gangloff, F Di Fiore, F Bibeau, A Lamy, G Bougeard in British Journal of Cancer (2009)

  6. Article

    Open Access

    Quality-of-life findings from a randomised phase-III study of XELOX vs FOLFOX-6 in metastatic colorectal cancer

    A phase-III trial showed the non-inferiority of oral capecitabine plus oxaliplatin (XELOX) vs 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) in terms of efficacy in first-line treatment of metastatic color...

    T Conroy, M Hebbar, J Bennouna, M Ducreux, M Ychou, G Llédo in British Journal of Cancer (2010)

  7. No Access

    Article

    A large-scale candidate gene approach identifies SNPs in SOD2 and IL13 as predictive markers of response to preoperative chemoradiation in rectal cancer

    Neoadjuvant radiochemotherapy followed by total mesorectal excision is now the standard treatment for locally advanced rectal cancer. However, tumor response to chemoradiation varies widely among individuals a...

    A Ho-Pun-Cheung, E Assenat, C Bascoul-Mollevi, F Bibeau in The Pharmacogenomics Journal (2011)

  8. Article

    Open Access

    Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial

    This trial evaluated the feasibility and efficacy of combined sorafenib and irinotecan (NEXIRI) as second- or later-line treatment of patients with KRAS-mutated metastatic colorectal cancer (mCRC), who had progre...

    E Samalin, O Bouché, S Thézenas, E Francois, A Adenis in British Journal of Cancer (2014)